Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
97.78
-0.63 (-0.64%)
At close: May 9, 2025, 4:00 PM
97.68
-0.10 (-0.10%)
After-hours: May 9, 2025, 7:35 PM EDT
Jazz Pharmaceuticals (JAZZ) Oncology Revenue Breakdown
History
| Date | Rylaze Enrylaze | Zepzelca | Defitellio Defibtrotide | Vyxeos | Erwinaze |
|---|---|---|---|---|---|
| Mar 31, 2025 | 402.33M | 308.25M | 209.55M | 160.12M | - |
| Dec 31, 2024 | 410.85M | 320.32M | 216.57M | 162.60M | - |
| Sep 30, 2024 | 411.11M | 316.00M | 210.00M | 156.26M | - |
| Jun 30, 2024 | 417.19M | 308.15M | 191.91M | 151.77M | - |
| Mar 31, 2024 | 411.05M | 297.45M | 192.60M | 142.82M | - |
| Dec 31, 2023 | 394.23M | 289.53M | 184.00M | 147.50M | - |
| Sep 30, 2023 | 373.45M | 287.49M | 173.57M | 130.85M | - |
| Jun 30, 2023 | 342.11M | 279.82M | 175.29M | 131.09M | - |
| Mar 31, 2023 | 313.37M | 277.76M | 183.88M | 130.92M | - |
| Dec 31, 2022 | 281.66M | 269.91M | 194.29M | 127.98M | - |
| Sep 30, 2022 | 265.64M | 262.78M | 196.15M | 132.48M | - |
| Jun 30, 2022 | 212.80M | 264.17M | 204.40M | 137.10M | - |
| Mar 31, 2022 | 139.85M | 251.81M | 197.80M | 134.66M | - |
| Dec 31, 2021 | 85.63M | 246.81M | 197.93M | 134.06M | - |
| Sep 30, 2021 | 20.67M | 235.41M | 210.88M | 130.29M | - |
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.